RecruitingPhase 3ACTRN12605000082606

INSTEP Trial

Influence of NSAID on Short Term Efficacy of Pleurodesis for recurrent pneumothorax

Sponsor

Gavin M Wright

Enrollment

100 participants

Start Date

Dec 15, 2004

Study Type

Interventional

Conditions

Recurrent or persistent pneumothorax requiring VATS pleurodesis

Summary

For pain relief after VATS pleurodesis, patients are given either Celebrex or Placebo for 5 days plus any other required analgesics. We aim to determine whether there is any difference in failure of the lung to adhere to the lining of the chest.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study, called the INSTEP Trial, looks at whether taking a pain relief medication called Celebrex (celecoxib) after a surgical procedure to treat a collapsed or recurrent lung (pleurodesis via VATS) affects how well the lung sticks to the chest wall. This sticking is important for the procedure to be successful. The study will compare patients who take Celebrex to those who take a placebo (dummy pill). You may be eligible if: - You are 18 years of age or older - You are having a surgical procedure (pleurodesis) for a recurrent or persistent collapsed lung (pneumothorax) You may NOT be eligible if: - You regularly take NSAID pain medications (like ibuprofen) and cannot stop them for more than 24 hours before surgery - You have kidney problems (renal impairment) Talk to your doctor about whether this trial might be right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Print for Your Doctor Check Your Eligibility

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Celebrex 200mg bd 5 days

Locations(1)

St Vincent's Hospital (Melbourne) Ltd - Fitzroy

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000082606